Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Da Vià MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kortüm KM.

Oncologist. 2020 Feb;25(2):112-118. doi: 10.1634/theoncologist.2019-0356. Epub 2019 Oct 18.

2.

Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.

Zhou X, Steinhardt MJ, Düll J, Krummenast F, Danhof S, Meckel K, Nickel K, Grathwohl D, Leicht HB, Rosenwald A, Einsele H, Rasche L, Kortüm M.

Eur J Haematol. 2020 Jan 10. doi: 10.1111/ejh.13382. [Epub ahead of print]

PMID:
31922303
3.

A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.

Schürch CM, Rasche L, Frauenfeld L, Weinhold N, Fend F.

Virchows Arch. 2019 Dec 17. doi: 10.1007/s00428-019-02725-3. [Epub ahead of print] Review.

PMID:
31848687
4.

Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.

Mohan M, Weinhold N, Schinke C, Thanedrarajan S, Rasche L, Sawyer JR, Tian E, van Rhee F, Zangari M.

Br J Haematol. 2019 Dec 9. doi: 10.1111/bjh.16292. [Epub ahead of print]

PMID:
31820442
5.

On-target restoration of a split T cell-engaging antibody for precision immunotherapy.

Banaszek A, Bumm TGP, Nowotny B, Geis M, Jacob K, Wölfl M, Trebing J, Kucka K, Kouhestani D, Gogishvili T, Krenz B, Lutz J, Rasche L, Hönemann D, Neuweiler H, Heiby JC, Bargou RC, Wajant H, Einsele H, Riethmüller G, Stuhler G.

Nat Commun. 2019 Nov 26;10(1):5387. doi: 10.1038/s41467-019-13196-0.

6.

CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Da Vià MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kortüm KM.

Oncologist. 2019 Oct 18. pii: theoncologist.2019-0356. doi: 10.1634/theoncologist.2019-0356. [Epub ahead of print]

7.

IKZF1/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma.

Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Da Viá M, Sanchez R, Bruins L, Demler T, Müller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio-Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, Stühmer T, Kortüm KM.

Haematologica. 2019 Sep 26. pii: haematol.2019.217943. doi: 10.3324/haematol.2019.217943. [Epub ahead of print]

8.

Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.

Pfuhl C, Grittner U, Gieß RM, Scheel M, Behrens JR, Rasche L, Pache FC, Wenzel R, Brandt AU, Bellmann-Strobl J, Paul F, Ruprecht K, Oechtering J.

Neurology. 2019 Oct 8;93(15):e1439-e1451. doi: 10.1212/WNL.0000000000008237. Epub 2019 Sep 9.

PMID:
31501228
9.

The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT.

Einsele H, Rasche L, Topp MS, Martin Kortüm K, Duell J.

Bone Marrow Transplant. 2019 Aug;54(Suppl 2):721-726. doi: 10.1038/s41409-019-0596-z.

PMID:
31431702
10.

Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?

Rasche L, Kumar M, Gershner G, Samant R, Van Hemert R, Heidemeier A, Lapa C, Bley T, Buck A, McDonald J, Hillengass J, Epstein J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Theranostics. 2019 Jul 9;9(16):4756-4763. doi: 10.7150/thno.33289. eCollection 2019.

11.

Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness.

Munawar U, Rasche L, Müller N, Vogt C, Da-Via M, Haertle L, Arampatzi P, Dietrich S, Roth M, Garitano-Trojaola A, Steinhardt MJ, Strifler S, Gallardo M, Martinez-Lopez J, Bargou RC, Heckel T, Einsele H, Stühmer T, Kortüm KM, Barrio S.

Blood. 2019 Sep 5;134(10):836-840. doi: 10.1182/blood.2019000080. Epub 2019 Jul 24. No abstract available.

PMID:
31340981
12.

Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research.

Loda S, Krebs J, Danhof S, Schreder M, Solimando AG, Strifler S, Rasche L, Kortüm M, Kerscher A, Knop S, Puppe F, Einsele H, Bittrich M.

J Clin Med. 2019 Jul 9;8(7). pii: E999. doi: 10.3390/jcm8070999.

13.

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.

Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H.

J Clin Med. 2019 Jul 9;8(7). pii: E997. doi: 10.3390/jcm8070997. Review.

14.

Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor.

Strunz PP, Schmalzing M, Heidemeier A, Rasche L, Einsele H, Kortüm KM.

Leuk Lymphoma. 2019 Dec;60(14):3573-3576. doi: 10.1080/10428194.2019.1636981. Epub 2019 Jul 18. No abstract available.

PMID:
31317812
15.

Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma.

Lapa C, Kircher M, Da Via M, Schreder M, Rasche L, Kortüm KM, Einsele H, Buck AK, Hänscheid H, Samnick S.

Clin Nucl Med. 2019 Aug;44(8):620-624. doi: 10.1097/RLU.0000000000002638.

PMID:
31274607
16.

Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma.

Lapa C, Kircher M, Da Via M, Schreder M, Rasche L, Kortüm KM, Einsele H, Buck AK, Hänscheid H, Samnick S.

Clin Nucl Med. 2019 Jun 13. doi: 10.1097/RLU.0000000000002638. [Epub ahead of print]

PMID:
31205144
17.

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.

Duell J, Lukic DS, Karg M, Reusch U, Koch J, Zhukovsky EA, Rajkovic E, Treder M, Rasche L, Eisele F, Einsele H, Topp MS.

J Immunother. 2019 Jun;42(5):180-188. doi: 10.1097/CJI.0000000000000267.

PMID:
31090657
18.

[Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].

Rasche L, Einsele H, Nitschmann S.

Internist (Berl). 2019 Jun;60(6):658-660. doi: 10.1007/s00108-019-0592-9. German. No abstract available.

PMID:
30941437
19.

Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica.

Pasquier B, Borisow N, Rasche L, Bellmann-Strobl J, Ruprecht K, Niendorf T, Derfuss TJ, Wuerfel J, Paul F, Sinnecker T.

Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e541. doi: 10.1212/NXI.0000000000000541. eCollection 2019 May.

20.

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.

Rasche L, Kortüm KM, Raab MS, Weinhold N.

Int J Mol Sci. 2019 Mar 12;20(5). pii: E1248. doi: 10.3390/ijms20051248. Review.

21.

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.

Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG.

Haematologica. 2019 Jul;104(7):1440-1450. doi: 10.3324/haematol.2018.202200. Epub 2019 Feb 7.

22.

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Leukemia. 2019 Jul;33(7):1713-1722. doi: 10.1038/s41375-018-0329-0. Epub 2018 Dec 20.

23.

[Pathogenesis of multiple myeloma].

Rasche L, Weinhold N.

Internist (Berl). 2019 Jan;60(1):3-9. doi: 10.1007/s00108-018-0529-8. Review. German.

PMID:
30536029
24.

Ozanimod for the treatment of relapsing remitting multiple sclerosis.

Rasche L, Paul F.

Expert Opin Pharmacother. 2018 Dec;19(18):2073-2086. doi: 10.1080/14656566.2018.1540592. Epub 2018 Nov 8.

PMID:
30407868
25.

MRI Markers and Functional Performance in Patients With CIS and MS: A Cross-Sectional Study.

Rasche L, Scheel M, Otte K, Althoff P, van Vuuren AB, Gieß RM, Kuchling J, Bellmann-Strobl J, Ruprecht K, Paul F, Brandt AU, Schmitz-Hübsch T.

Front Neurol. 2018 Aug 29;9:718. doi: 10.3389/fneur.2018.00718. eCollection 2018.

26.

Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic.

Morgan GJ, Rasche L.

Expert Rev Hematol. 2018 Jul;11(7):513-523. doi: 10.1080/17474086.2018.1489718. Epub 2018 Jun 26. Review.

PMID:
29944024
27.

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.

Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N.

Blood. 2018 Jul 5;132(1):59-66. doi: 10.1182/blood-2018-04-842880. Epub 2018 May 21.

28.

Kinase domain activation through gene rearrangement in multiple myeloma.

Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA.

Leukemia. 2018 Nov;32(11):2435-2444. doi: 10.1038/s41375-018-0108-y. Epub 2018 Mar 23.

29.

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.

Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ.

Haematologica. 2018 Jun;103(6):1047-1053. doi: 10.3324/haematol.2017.177139. Epub 2018 Mar 22.

30.

Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance.

Danhof S, Schreder M, Knop S, Rasche L, Strifler S, Löffler C, Gogishvili T, Einsele H, Hudecek M.

Haematologica. 2018 Mar;103(3):e126-e129. doi: 10.3324/haematol.2017.178947. Epub 2017 Nov 30. No abstract available.

31.

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N.

Nat Commun. 2017 Aug 16;8(1):268. doi: 10.1038/s41467-017-00296-y.

32.

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.

Besse A, Stolze SC, Rasche L, Weinhold N, Morgan GJ, Kraus M, Bader J, Overkleeft HS, Besse L, Driessen C.

Leukemia. 2018 Feb;32(2):391-401. doi: 10.1038/leu.2017.212. Epub 2017 Jul 5.

33.

Haematological cancer: Where are we now with the treatment of multiple myeloma?

Morgan GJ, Rasche L.

Nat Rev Clin Oncol. 2017 Aug;14(8):461-462. doi: 10.1038/nrclinonc.2017.82. Epub 2017 Jun 13. No abstract available.

PMID:
28607521
34.

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.

Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ.

Haematologica. 2017 Sep;102(9):e364-e367. doi: 10.3324/haematol.2017.168872. Epub 2017 May 26. No abstract available.

35.

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.

Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ.

Haematologica. 2017 Aug;102(8):e313-e316. doi: 10.3324/haematol.2017.165217. Epub 2017 May 18. No abstract available.

36.

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.

Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Blood. 2017 Jul 6;130(1):30-34. doi: 10.1182/blood-2017-03-774422. Epub 2017 Apr 21.

37.

Immunologic approaches for the treatment of multiple myeloma.

Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE.

Cancer Treat Rev. 2017 Apr;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. Epub 2017 Apr 6. Review.

38.

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.

Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ.

Oncotarget. 2017 Apr 25;8(17):27854-27867. doi: 10.18632/oncotarget.15718.

39.

Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis.

Gieß RM, Pfuhl C, Behrens JR, Rasche L, Freitag E, Khalighy N, Otto C, Wuerfel J, Brandt AU, Hofmann J, Eberspächer B, Bellmann-Strobl J, Paul F, Ruprecht K.

PLoS One. 2017 Apr 7;12(4):e0175279. doi: 10.1371/journal.pone.0175279. eCollection 2017.

40.

Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.

Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S.

Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5.

PMID:
28382503
41.

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA.

Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12.

42.

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.

Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, Rasche L, Hartmann E, Dandekar T, Einsele H, Topp MS.

Leukemia. 2017 Oct;31(10):2181-2190. doi: 10.1038/leu.2017.41. Epub 2017 Jan 25.

43.

Increasing social welfare by taxing pesticide externalities in the Indian cotton sector.

Rasche L, Dietl A, Shakhramanyan N, Pandey D, Schneider UA.

Pest Manag Sci. 2016 Dec;72(12):2303-2312. doi: 10.1002/ps.4275. Epub 2016 Apr 15.

PMID:
26990306
44.

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT, Rasche L, Mądry K, Woszczyk D, Raźny M, Usnarska-Zubkiewicz L, Knopińska-Posłuszny W, Wojciechowska M, Guzicka-Kazimierczak R, Joks M, Grosicki S, Ciepłuch H, Rymko M, Vesole DH, Castillo JJ.

Br J Haematol. 2016 Dec;175(5):884-891. doi: 10.1111/bjh.14328. Epub 2016 Sep 29.

PMID:
27682187
45.

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.

Rasche L, Röllig C, Stuhler G, Danhof S, Mielke S, Grigoleit GU, Dissen L, Schemmel L, Middeke JM, Rücker V, Schreder M, Schetelig J, Bornhäuser M, Einsele H, Thiede C, Knop S.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1988-1996. doi: 10.1016/j.bbmt.2016.08.024. Epub 2016 Aug 31.

46.

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ.

Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11.

47.

Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: A peptide microarray-based case-control study.

Schlemm L, Giess RM, Rasche L, Pfuhl C, Wakonig K, Behrens JR, Scheibenbogen C, Bellmann-Strobl J, Paul F, Reimer U, Ruprecht K.

J Neuroimmunol. 2016 Aug 15;297:56-62. doi: 10.1016/j.jneuroim.2016.05.012. Epub 2016 May 13.

PMID:
27397076
48.

A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.

Rasche L, Menoret E, Dubljevic V, Menu E, Vanderkerken K, Lapa C, Steinbrunn T, Chatterjee M, Knop S, Düll J, Greenwood DL, Hensel F, Rosenwald A, Einsele H, Brändlein S.

Clin Cancer Res. 2016 Sep 1;22(17):4341-9. doi: 10.1158/1078-0432.CCR-15-3111. Epub 2016 Mar 30.

49.

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ.

Am J Hematol. 2016 Jun;91(6):575-80. doi: 10.1002/ajh.24351. Epub 2016 Apr 24.

50.

Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study.

Rasche L, Heiserich L, Behrens JR, Lenz K, Pfuhl C, Wakonig K, Gieß RM, Freitag E, Eberle C, Wuerfel J, Dörr J, Bauer P, Bellmann-Strobl J, Paul F, Roggenbuck D, Ruprecht K.

PLoS One. 2016 Jan 28;11(1):e0147968. doi: 10.1371/journal.pone.0147968. eCollection 2016.

Supplemental Content

Loading ...
Support Center